Does a pre-IPO biotech company need a fractional CRO in 2027?
Direct Answer
Pre-IPO biotechs face a unique revenue challenge: you must demonstrate predictable, scalable commercial traction to underwriters and institutional investors, yet your product may still be early-stage or facing long sales cycles with hospital systems and research institutions. A fractional CRO can build your go-to-market infrastructure, coach your existing sales team, and create the revenue processes that due diligence teams expect — without the long-term commitment of a full-time C-suite hire. The decision hinges on whether you have a credible revenue leader already in place and whether your burn rate allows for a flexible, part-time executive. If your board is asking for a revenue plan and you do not have one, a fractional CRO is likely the fastest fix.
The Pre-IPO Biotech Revenue Challenge
Biotech companies going public in 2027 face a market that demands revenue visibility. The days of pre-revenue IPOs are largely behind us; underwriters now expect to see commercial traction, pipeline discipline, and forecasting accuracy that can withstand public market scrutiny. If your company is still operating with ad-hoc sales processes, a founder-led revenue function, or a sales team that lacks enterprise selling skills, you have a problem.
The revenue cycle in biotech is long and complex. You are selling to research institutions, hospitals, and pharmaceutical partners — organizations with procurement cycles that can span 9 to 18 months. Your buyers include principal investigators, grant administrators, hospital procurement teams, and sometimes regulatory stakeholders. A fractional CRO who has worked in this environment understands how to compress those cycles without damaging relationships.
What a Fractional CRO Actually Does for a Pre-IPO Biotech
A fractional CRO is not a part-time salesperson. The role is executive-level revenue leadership delivered on a flexible basis. For a pre-IPO biotech, the work typically includes:
- Building the revenue infrastructure: Defining sales territories, compensation plans, CRM workflows (Salesforce or HubSpot), and pipeline stages that align with investor expectations.
- Coaching and developing the sales team: Many biotechs hire sales reps from academic or clinical backgrounds who lack enterprise sales training. A fractional CRO brings structured methodology — using tools like Gong for conversation intelligence, Outreach or Salesloft for sequencing, and Clari for forecasting.
- Creating the IPO-ready revenue narrative: Investors want to see a repeatable sales motion, a clear total addressable market (TAM) story, and evidence of customer concentration risk management. The fractional CRO helps craft that narrative alongside the CFO and CEO.
- Managing the board and investor relationship: Fractional CROs often attend board meetings, present revenue updates, and answer due diligence questions from underwriters.
When a Fractional CRO Is the Wrong Choice
Honesty requires admitting that a fractional CRO is not always the answer. If your biotech already has a strong, experienced VP of Sales who has taken a company public before, and your revenue processes are already documented and investor-ready, a fractional CRO may add unnecessary cost and confusion. Similarly, if your revenue is still zero or negligible and your timeline to IPO is more than 24 months away, you might be better served by a full-time VP of Sales who can grow with the company.
Another scenario where fractional does not fit: if your board and investors insist on a full-time CRO as a condition of the IPO. Some underwriters view fractional leadership as a sign of instability, particularly in the life sciences sector. In that case, you may need to hire full-time and accept the higher cost.
How to Find and Vet a Fractional CRO for Biotech
The market for fractional CROs has grown significantly by 2027, but quality varies. You want someone who has direct biotech or life sciences experience — not just general B2B SaaS. Look for candidates who have held CRO or VP of Sales roles at companies that successfully went public or were acquired. Check their familiarity with regulatory considerations in biotech sales, such as compliance with Sunshine Act reporting or interactions with key opinion leaders (KOLs).
Cost Structure and Engagement Models
Fractional CRO pricing in 2027 for biotech companies typically falls into these ranges:
- Advisory-only: $8k–$12k per month for 1–2 days per week of strategy, board prep, and high-level coaching. No hands-on pipeline management.
- Hybrid advisory and execution: $12k–$18k per month for 2–3 days per week, including deal reviews, pipeline management, and direct involvement in key account strategy.
- Hands-on interim CRO: $18k–$25k+ per month for 3–4 days per week, effectively acting as the full-time CRO but on a contract basis. Often includes a commitment to hire and train a successor.
Most engagements run 3 to 12 months, with the option to extend or convert to full-time. Some fractional CROs will accept a small equity component in lieu of higher cash comp, but this is less common in pre-IPO companies where equity is already heavily allocated.
The Risk of Waiting Too Long
One of the most common mistakes pre-IPO biotech CEOs make is waiting until the S-1 filing is imminent before addressing revenue leadership gaps. Underwriters will flag missing revenue processes during due diligence, and fixing them under time pressure is expensive and stressful. A fractional CRO brought in 6 to 12 months before the IPO can build the systems, train the team, and create the documentation that makes the process smoother.
The opposite risk — bringing in a fractional CRO too early — is less severe. If you engage one when your revenue is still minimal, you may pay for services you do not yet need. The sweet spot is when you have initial commercial traction (a few paying customers, a repeatable pilot process) but need to scale and professionalize before the public offering.
FAQ
What is the difference between a fractional CRO and a VP of Sales? A fractional CRO is an executive-level role focused on overall revenue strategy, team structure, forecasting, and board readiness. A VP of Sales typically owns day-to-day sales execution and team management. In pre-IPO biotech, you may need both, but the fractional CRO often acts as the strategic layer while the VP of Sales runs the team.
Can a fractional CRO help with the IPO roadshow? Yes, but their role is typically behind the scenes — preparing the revenue narrative, building the financial models, and coaching the CEO on investor questions. They rarely join the roadshow itself unless the company is very small.
How do I know if a fractional CRO has biotech experience? Ask for specific examples of companies they have worked with, the stage of those companies, and the nature of the sales cycles. Request references from CEOs in the life sciences space. Look for familiarity with terms like KOLs, grant cycles, institutional review boards, and Sunshine Act compliance.
Will a fractional CRO conflict with my existing sales leadership? This depends on how you frame the role. If you position the fractional CRO as a coach and strategist who reports to the CEO, and your VP of Sales reports to the fractional CRO, it can work well. If you create a confusing dual-reporting structure, it will cause friction. Clear role definition is essential.
What happens after the IPO? Does the fractional CRO stay? Most fractional CRO engagements end 3 to 6 months after the IPO, once the company has a stable revenue function and a full-time CRO or VP of Sales in place. Some companies convert the fractional CRO to a part-time board advisor.
How do I evaluate a fractional CRO's fit with my board and investors? Ask the fractional CRO to present a sample board deck or revenue review. See how they handle tough questions. Your board will want to know that this person can command a room and speak credibly about revenue to sophisticated investors.
Sources
- Pavilion — Community for revenue leaders
- RevOps Co-op — Revenue operations community
- Harvard Business Review — Articles on sales leadership and organizational design
- First Round Review — Startup leadership and go-to-market advice
- SaaStr — SaaS and subscription revenue insights
- LinkedIn — Search for fractional CROs with biotech experience
People also search for: fractional cro · hire a fractional cro · fractional cro near me · fractional cro cost